Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine

References

• Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211–1221. doi:10.1007/s10096-019-03539-630945014
   PubMed Web of Science ®Google Scholar
• Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9:1.
   Web of Science ®Google Scholar
• Marley C, El Hahi Y, Ferreira G, Woods L, Ramirez Villaescusa A. Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in clinical practice research datalink. Hum Vaccin Immunother. 2019;15(10):2475–2481. doi:10.1080/21645515.2019.158928830945972
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.29462280
   PubMed Web of Science ®Google Scholar
• Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: a retrospective case-control study. Anaerobe. 2019;59:126–130. doi:10.1016/j.anaerobe.2019.06.01631254655
   PubMed Web of Science ®Google Scholar
• Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother. 2020;64(4):e02169–e02219. doi:10.1128/AAC.02169-1931964789
   PubMed Web of Science ®Google Scholar
• Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health. 2017;7(1):010417. doi:10.7189/jogh.07.01041728607673
   PubMed Web of Science ®Google Scholar
• Cui Y, Dong D, Zhang L, et al. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infect Dis. 2019;19(1):1. doi:10.1186/s12879-019-4603-130606108
   PubMed Web of Science ®Google Scholar
• Natarajan M, Rogers MA, Bundy J, et al. Gender differences in non-toxigenic Clostridium difficile colonization and risk of subsequent C. difficile infection. Clin Res Infect Dis. 2015;2:2.
   Google Scholar
• Asempa T, Nicolau D. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging. 2017;12:1799–1809. doi:10.2147/CIA.S14908929123385
   PubMed Web of Science ®Google Scholar
• Jump RL. Clostridium difficile infection in older adults. Aging Health. 2013;9(4):403–414. doi:10.2217/ahe.13.3724955106
   PubMedGoogle Scholar
• Miranda-Katz M, Parmar D, Dang R, Alabaster A, Greenhow TL. Epidemiology and risk factors for community associated Clostridioides difficile in children. J Pediatr. 2020;221:99–106. doi:10.1016/j.jpeds.2020.02.00532171559
   PubMed Web of Science ®Google Scholar
• Tschudin-Sutter S, Tamma PD, Naegeli AN, Speck KA, Milstone AM, Perl TM. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin Infect Dis. 2013;57(12):1665–1672. doi:10.1093/cid/cit58124046303
   PubMed Web of Science ®Google Scholar
• Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing age has limited impact on risk of Clostridium difficile infection in an elderly population. Open Forum Infect Dis. 2018;5(7):7. doi:10.1093/ofid/ofy160
   Web of Science ®Google Scholar
• Kamboj M, Gennarelli R, Brite J, Sepkowitz K, Lipitz-Snyderman A. Risk for Clostridioides difficile infection among older adults with cancer. Emerg Infect Dis J. 2019;25(9):1683. doi:10.3201/eid2509.181142
   Web of Science ®Google Scholar
• Revolinski SL, Munoz-Price LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis. 2019;68(12):2144–2153. doi:10.1093/cid/ciy84530281082
   PubMed Web of Science ®Google Scholar
• Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis. 2013;1(1):19–35. doi:10.1177/204993611247217325165542
   PubMedGoogle Scholar
• Taking antibiotics increases your risk for C. diff infection. Center For Disease Control And Prevention; 2021. Available from: https://www.cdc.gov/cdiff/risk.html. Accessed June 15, 2021.
   Google Scholar
• Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int J Med Sci. 2019;16(5):630–635. doi:10.7150/ijms.3073931217729
   PubMed Web of Science ®Google Scholar
• Choucair J, Waked R, Haddad E, et al. Clostridioides difficile infections: epidemiology, correlations and treatment in a Lebanese cohort with use of ATLAS scoring. J Infect Dev Ctries. 2020;14(12):1461–1465. doi:10.3855/jidc.1318933378291
   PubMed Web of Science ®Google Scholar
• Alammari KM, Thabit AK. Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration. Gut Pathog. 2021;13(1):10. doi:10.1186/s13099-021-00405-933593421
   PubMed Web of Science ®Google Scholar
• Elgendy SG, Aly SA, Fathy R, Deaf EAE, Abu Faddan NH, Abdel Hameed MR. Clinical and microbial characterization of toxigenic Clostridium difficile isolated from antibiotic associated diarrhea in Egypt. Iran J Microbiol. 2020;12(4):296–304.32994900
   PubMed Web of Science ®Google Scholar
• Castro I, Tasias M, Calabuig E, Salavert M. Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. Rev Esp Quimioter. 2019;32(Suppl 2):47–54.31475811
   PubMed Web of Science ®Google Scholar
• NICE. Clostridium difficile infection: risk with broad-spectrum antibiotics; 2021. Available from: https://www.nice.org.uk/advice/esmpb1/chapter/Key-points-from-the-evidence. Accessed November 1, 2021.
   Google Scholar
• Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. Postgrad Med J. 1987;63(745):993–994. doi:10.1136/pgmj.63.745.9933451227
   PubMed Web of Science ®Google Scholar
• Hecht JR, Olinger EJ. Clostridium difficile colitis secondary to intravenous vancomycin. Dig Dis Sci. 1989;34(1):148–149. doi:10.1007/BF15361722910675
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–2056. doi:10.1111/j.1572-0241.2007.01275.x17509031
   PubMed Web of Science ®Google Scholar
• Patil R, Blankenship L. Proton pump inhibitors and clostridium difficile infection: are we propagating an already rapidly growing healthcare problem? Gastroenterol Res. 2013;6(5):171. doi:10.4021/gr575w
   Google Scholar
• Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia. Clin Drug Investig. 2010;30(8):559–563. doi:10.2165/11537230-000000000-00000
   Web of Science ®Google Scholar
• Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol. 2012;107(7):1020–1021. doi:10.1038/ajg.2012.17422764024
   PubMed Web of Science ®Google Scholar
• Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile Infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017;11(6):781–788. doi:10.5009/gnl1656828506028
   PubMed Web of Science ®Google Scholar
• Haider F, Raza N, Komar M, Rahman O, Sartorius J, Kirchner H. Proton pump inhibitor use elevates the risk of severe Clostridium difficile colitis. J Gastroenterol Hepatol Res. 2012;1(4):53–56.
   Google Scholar
• Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and severity of hospital-acquired Clostridium difficile infection in patients taking proton pump inhibitors. Pharmacotherapy. 2016;36(9):986–993. doi:10.1002/phar.180127455386
   PubMed Web of Science ®Google Scholar
• Juneau C, Mendias EP, Wagal N, et al. Community-acquired Clostridium difficile infection: awareness and clinical implications. J Nurse Pract. 2013;9(1):1–6. doi:10.1016/j.nurpra.2012.10.00723814528
   PubMedGoogle Scholar
• Oake N, Taljaard M, Van Walraven C, Wilson K, Roth V, Forster AJ. The effect of hospital-acquired clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010;170(20):1804–1810. doi:10.1001/archinternmed.2010.40521059973
   PubMedGoogle Scholar
• Zumla A. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Lancet Infect Dis. 2010;10(5):303–304. doi:10.1016/S1473-3099(10)70089-X
   Google Scholar
• Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol. 2003;41(2):531–534. doi:10.1128/JCM.41.2.531-534.200312574241
   PubMed Web of Science ®Google Scholar
• Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247–263. doi:10.1128/CMR.18.2.247-263.200515831824
   PubMed Web of Science ®Google Scholar